Citations

Clear

4799 citation(s) found for "Yu, Jennifer".

NIMG-28. VALIDATION OF SINGLE-DOSE DSC-MRI PROTOCOLS FOR ROBUST PERFUSION ASSESSMENT IN BRAIN TUMORS
Quarles, C. Chad , Semmineh, Natenael , Fuentes, Alberto, Nespodzany, Ashley , Alhilai, Lea, Karis, John P. , Rand, Scott D. , Dardis, Chris, Braun, Kelly, Connelly, Jennifer , Hu, Leland , Boxerman, J. L., Stokes, Ashley M. , Bell, Laura C. , Prah, Melissa A. , Connelly, Jennifer , Zhou, Yuxiang , Schmainda, Kathleen M

Mayo Clinic

Neuro-Oncology | November 11, 2019 | Volume: 21 | Issue: Supplement_6 | Pages: vi167-vi167

10.1093/neuonc/noz175.699 Get It

Abstract Dynamic susceptibility contrast (DSC) MRI measures of brain tumor cerebral blood volume (CBV) are able to predict grade, overall survival and response to treatment. Wide-spread acceptance of DSC-MRI has been challenged by the need to balance contrast agent dose and CBV accuracy. The goal of this study was to identify and validate single-dose, BTIP compliant, DSC-MRI protocols. Using a validated, patient-based DRO, we evaluated CBV accuracy across a range of acquisition parameters (field strength, TR, TE, flip angle, multi-echo acquisitions, dosing protocols) and post-processing steps. To validate the optimal protocols, we next collected DSC-MRI data following ASFNR’s recommended “double – dose” approach, where a single-dose preload (to minimize T1 effects) is given prior to a second bolus injection (for DSC-MRI data acquisition). The single-dose DSC-MRI data was collected during the preload bolus injection. Consistency of the derived CBV data, visual agreement and data characteristics (e.g. CNR) was statistically evaluated. When using a single-dose and routine single-echo pulse sequence, the DRO analysis found that a low flip angle (LFA = 30o) and 30ms TE provided the highest CBV accuracy (concordance correlation coefficient (CCC) = 0.92) and precision (coefficient of variation (CV) = 8.2%)). For comparison, the maximum accuracy found with the DRO utilizes a double-dose injection protocol and yielded a CCC of 0.98 and CV of 6.8%. Single-dose, multi-echo acquisitions provided higher accuracy than the LFA data and matched that found with the double-dose approach. In patients (data collection ongoing), the agreement between single-dose LFA (n > 40) or multi-echo (n > 40) based CBV values and the reference double-dose approach was very high (CCC > 0.94) and were statistically equivalent. Optimized single-dose DSC-MRI protocols provide highly accurate CBV data, use lower doses of contrast agent, and simplify scan procedures, indicating their potential for robust use in clinical practice and trials.
SCIDOT-46. MicroRNA NANOCELL THERAPY FOR GLIOBLASTOMA
Khan, Muhammad Babar , Ruggieri, Rosamaria, MacDiarmid, Jennifer A. , Brahmbhatt, Himanshu , Boockvar, John A. , Symons, Marc , Tran, Nhan L. , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | November 11, 2019 | Volume: 21 | Issue: Supplement_6 | Pages: vi281-vi281

10.1093/neuonc/noz175.1182 Get It

Abstract Therapeutic resistance stemming from inter and intra-tumoral heterogeneity is a significant impediment towards development of effective therapeutics for glioblastoma. We hypothesized that microRNAs can potentially counteract resistance emanating from such heterogeneity as they simultaneously modulate the expression of multiple proteins. We identified microRNA-34a as a unique microRNA which modulates multiple oncoproteins in GBM using two different in silico approaches. We investigated the therapeutic effects of microRNA-34a in three primary patient-derived xenografts (PDX) representing classical (GBM6), proneural (GBM118) and mesenchymal (GBM118) subtypes; four established cell lines (T98G, U251, A172, LN229) and two cell lines with acquired resistance to temozolomide (A172-TR, LN229-TR) in vitro. Glioblastoma cell cultures showed variable responses to temozolomide but microRNA-34a inhibited proliferation in all cell cultures. Furthermore, microRNA-34a also sensitized all tested cell lines to temozolomide (combination index < 0.8, p=.03) and radiation treatment (dose enhancement factor 1.7–2.2, p=0.02). Mechanistically, microRNA 34a down-regulates at least six distinct therapeutic resistance proteins. Importantly, these resistance proteins are expressed in distinct spatial niches and are prognostic for patient survival based on our analysis of the cancer genome atlas (TCGA) data. For in vivo delivery of microRNA-34a, we utilized nanocells which are derived from genetically modified bacteria, loaded with microRNA-34a and tagged with a bispecific antibody targeting EGFR. Nanocells were injected intravenously while temozolomide was administered by oral gavage in an orthotopic PDX model. We confirmed delivery of microRNA-34a to tumor by observing down-regulation of cMet and phosphorylated Akt in treated mice. Importantly, microRNA-34a nanocells resulted in significant reduction in tumor growth (p=0.021), increased survival (p<0.001) with microRNA-34a monotherapy and synergy in combination with temozolomide in vivo. Taken together, our results suggest that delivery of miR-34a may be a powerful new adjuvant for the treatment of glioblastoma in combination with temozolomide that can mitigate both inter- and intra-tumor heterogeneity.
Therapeutic plasma exchange for neuromyelitis optica spectrum disorder: A multicenter retrospective study by the ASFA neurologic diseases subcommittee
Ipe, Tina S. , Fernando, Leonor P. , Gokhale, Amit , Johnson, Andrew D., Kim, Haewon C., Monis, Grace F., Mo, Yunchun D., Morgan, Shanna, Sanford, Kimberly , Schmidt, Amy E. , Wu, Yanyun , Yamada, Chisa , Wong, Edward C.C. , Webb, Jennifer , Wu, Yanyun , Yamada, Chisa , Ipe, Tina S , Raval, Jay S. , Jacquot, Cyril , Pagano, Monica B. , Pham, Huy P. , Schwartz, Joseph E. , Waldman, Amy , Winters, Jeffrey L.

Mayo Clinic

Journal of Clinical Apheresis | November 9, 2019 | Volume: 35 | Issue: 1 | Pages: 25-32

10.1002/jca.21754 | PMID 31705563 Get It

AbstractImportanceNeuromyelitis optica/neuromyelitis optica spectrum disorder patients' response to therapeutic plasma exchange (TPE) is currently incompletely characterized.ObjectiveOur study aims to understand the clinical status improvement of neuromyelitis optica/neuromyelitis optica spectrum disorder patients treated with TPE.Design, Setting, and ParticipantsThis is a multicenter retrospective study conducted between 1 January 2003 and 31 July 2017 at 13 US hospitals performing apheresis procedures. Subjects studied were diagnosed with neuromyelitis optica/neuromyelitis optica spectrum disorder who received TPE during presentation with acute disease.Main Outcomes and MeasuresThe primary outcome was clinical status improvement in patients treated with TPE. Secondary measures were procedural and patient characteristics associated with response to treatment.ResultsWe evaluated 114 patients from 13 institutions. There was a female predilection. The largest ethnic group affected was non‐Hispanic Caucasian. The average age of diagnosis was 43.1 years. The average time to diagnosis was 3.1 years. On average, five procedures were performed during each treatment series. The most commonly performed plasma volume exchange was 1.0 to 1.25 using 5% albumin as replacement fluid. Most patients (52%) did not require an additional course of TPE and noted “mild” to “moderate” clinical status improvement. Maximal symptom improvement appeared by the fourth or fifth TPE treatment.Conclusion and RelevanceTPE improved the clinical status of patients. Adults responded more favorably than children. Procedural characteristics, including number of TPEs, plasma volume exchanged, and replacement fluid used, were similar between institutions. TPE was well‐tolerated and had a low severe adverse event profile.
THE RELATIONSHIP OF APOE ε4 TO THE RELATIVE TIMES AND HAZARDS OF DEMENTIA
Powell, Danielle, Kuo, Pei‐Lun, Gottesman, Rebecca, Palta, Priya, Gross, Alden L. , Deal, Jennifer A. , Knopman, David S.

Mayo Clinic

Innovation in Aging | November 9, 2019 | Volume: 3 | Issue: Supplement_1 | Pages: S587-S587

10.1093/geroni/igz038.2175 Get It

Abstract Although APOE ε4 is an established risk factor for dementia, it is unclear whether it is associated with elevated risk or earlier symptom onset. Longitudinal study of 10,400 white-race individuals in the ARIC cohort followed from age 60 to incident dementia diagnosis, death, or censoring. All-cause dementia was defined using standardized algorithms incorporating longitudinal cognitive change, proxy report, and hospital or death certificate dementia codes. Death was ascertained via the National Death Index and death certificates. We used a parametric mixture of generalized gamma distributions to simultaneously estimate the distribution of event times and the proportion of individuals who experience each outcome (i.e., dementia and its competing risk, dementia-free death) by APOE ε4 status (≥ 1 allele vs. no alleles). Age-adjustment was through use of age as the time scale. APOE ε4 carrier status was associated with a doubling of the overall frequency of dementia incidence to 25% compared to 13% (p &lt; 0.001) in non- ε4 carriers. The distributions of time to dementia was modified by APOE ε4 status (p=0.007): median time to dementia onset among APOE ε4 carriers was 81.9 years compared to 83.3 years in non-APOE ε4 carriers (p = 0.005). No differences in results were found by sex. APOE ε4 carrier status is associated with both elevated risk and earlier time to dementia onset. These findings clarify the causal role of APOE in dementia etiology, could help better identify at-risk subgroups, and may help facilitate better research recruitment.
STRENGTHENING DEMENTIA CAREGIVING NETWORKS WITH TECHNOLOGIES: INTERSECTIONS OF POLICY, RESEARCH, AND PRACTICE
Bangerter, Lauren R. , Gruber, Melinda, Luetke-Stahlman, Hannah, Malley, Kelly A O, Ruggiano, Nicole , Wolff, Jennifer L.

Mayo Clinic

Innovation in Aging | November 9, 2019 | Volume: 3 | Issue: Supplement_1 | Pages: S451-S452

10.1093/geroni/igz038.1692 Get It

Abstract Both family caregivers and providers report numerous challenges to providing care for of adults with Alzheimer’s disease and related dementias (AD/RD). Many of these challenges stem from ineffective communication and coordination within the health and support service networks, including: (1) communication challenges posed by AD/RD patients; (2) communication barriers between caregivers and providers; and (3) communication barriers among providers across institutions. Caregivers increasingly rely on technology to fill gaps in their knowledge, identify social support, and learn how to execute more complex care demands. While technology has been suggested as an effective strategy for improving the quality of AD/RD care and support caregivers, the role that public policy and research can and should play in advancing the goal of such tech-based solutions is still emerging. This is especially true in respect to how technology can strengthen care networks for patients and caregivers who are racial/ethnic minorities and/or living in rural communities. This presentation will identify the role that past legislation (e.g. the Affordable Care Act, HITECH, Medicaid) has played, as well as the role that recent and proposed legislation (e.g. RAISE Caregiver Act, CARE Act, 21st Century Cures Act, BOLD Infrastructure for Alzheimer’s Act, Older American’s Act reauthorization) should play in strengthening the health, support networks that caregivers interact with to provide ongoing care. This presentation will also summarize the current state of research on caregiver technologies and discusses how future research and policy initiatives can promote the translation of tech-based interventions into everyday care settings.
CT angiogram findings in carotid-cavernous fistulas: stratification of imaging features to help radiologists avoid misdiagnosis
Benson, John C. , Rydberg, Charlotte H. , Johnson, Matthew P. , Geske, Jennifer R. , Brinjikji, Waleed , Cloft, Harry J. , Rydberg, Charlotte, DeLone, David R. , Geske, Jennifer, Cloft, Harry, Luetmer, Patrick H. , Benson, John , Geske, Jennifer , Lanzino, Giuseppe

Mayo Clinic

Acta Radiologica | November 8, 2019 | Volume: 61 | Issue: 7 | Pages: 945-952

10.1177/0284185119885119 | PMID 31698923 Get It

Background Carotid-cavernous fistulas (CCFs) are commonly misdiagnosed on computed tomography angiography (CTA). Purpose This study sought to identify the most sensitive and specific imaging features of CCFs on CTA. Material and Methods A retrospective review identified 18 consecutive patients suspected of having a CCF on CTA and subsequently underwent digital subtraction angiography (DSA). Two blinded reviewers assessed multiple findings on CTA: cavernous sinus asymmetry/enlargement; arterial-phase contrast in the cavernous sinus; proptosis; pre- or post-septal orbital edema; and dilated regional vasculature. Each was graded as positive, possible, and negative; “possible” was counted as positive. A third blinded reviewer served as a tiebreaker. Results Of 18 patients, nine were true-positive and nine were false-positive. Superior ophthalmic vein early enhancement and dilatation had 100.0% sensitivity (95% confidence interval [CI] 40.0–100.0) and 77.8% specificity (95% CI 44.4–100.0); arterial-phase contrast in the cavernous sinus had 88.9% sensitivity (95% CI 44.4–100.0) and 66.7% specificity (95% CI 18.5–90.1); peri-orbital edema had 88.9% sensitivity (95% CI 35.5–100.0) and 77.8% specificity (95% CI 22.2–100.0). The most specific markers of CCF were superior petrosal sinus and inferior ophthalmic vein dilatation/enhancement (100.0%, 95% CI 88.8–100.0 and 88.9%, 95% CI 44.4–100.0, respectively); the specificity of asymmetric cavernous enlargement was 44.4% (95% CI 11.1–77.7). Conclusions Among patients in whom a CCF is suspected on CTA, superior ophthalmic vein dilatation/enhancement and arterial-phase contrast within the cavernous sinus are the most sensitive findings. Asymmetric cavernous sinus enlargement has poor specificity and may result in false-positive diagnoses of CCFs. False positive cases were less likely to have an optimally timed contrast bolus.
Characteristics and utilisation of the Mayo Clinic Biobank, a clinic-based prospective collection in the USA: cohort profile
Ryu, Euijung , Hathcock, Matthew , Gupta, Ruchi , Bublitz, Joshua T., Bielinski, Suzette J. , Sauver, Jennifer L. St. , Sharp, Richard R. , Thibodeau, Stephen N. , Cicek, Mine , Hathcock, Matthew A, Takahashi, Paul Y. , St Sauver, Jennifer L, Meagher, Karen, Sharp, Richard R , St Sauver, Jennifer L , Bielinski, Suzette , Olson, Janet E. , Gupta, Ruchi, Meagher, Karen M. , Cerhan, James R.

Mayo Clinic

BMJ Open | November 7, 2019 | Volume: 9 | Issue: 11 | Pages: e032707

10.1136/bmjopen-2019-032707 | PMID 31699749 Get It

Purpose The Mayo Clinic Biobank was established to provide a large group of patients from which comparison groups (ie, controls) could be selected for case–control studies, to create a prospective cohort with sufficient power for common outcomes and to support electronic health record (EHR) studies. Participants A total of 56 862 participants enrolled (21% response rate) into the Mayo Clinic Biobank from Rochester, Minnesota (77%, n=43 836), Jacksonville, Florida (18%, n=10 368) and La Crosse, Wisconsin (5%, n=2658). Participants were all Mayo Clinic patients, 18 years of age or older and US residents. Findings to date Overall, 43% of participants were 65 years of age or older and female participants were more frequent (59%) than males at all sites. Most participants resided in the Upper Midwest regions of the USA (Minnesota, Iowa, Illinois or Wisconsin), Florida or Georgia. Self-reported race among Biobank participants was 90% white. Here we provide examples of the types of studies that have successfully utilised the resource, including (1) investigations of the population itself, (2) provision of controls for case–control studies, (3) genotype-driven research, (4) EHR-based research and (5) prospective recruitment to other studies. Over 270 projects have been approved to date to access Biobank data and/or samples; over 200 000 sample aliquots have been approved for distribution. Future plans The data and samples in the Mayo Clinic Biobank can be used for various types of epidemiological and clinical studies, especially in the setting of case–control studies for which the Biobank samples serve as control samples. We are planning cohort studies with additional follow-up and acquisition of genetic information on a large scale.
Potential Unintended Consequences Of Recent Shared Decision Making Policy Initiatives
Opel, Douglas J. , Kramer, Daniel B. , Edmonds, Brownsyne Tucker , Ladin, Keren , Peek, Monica E. , Peppercorn, Jeff, Tilburt, Jon C. , Blumenthal‐Barby, Jennifer , Dickert, Neal W.

Mayo Clinic

Health Affairs | November 4, 2019 | Volume: 38 | Issue: 11 | Pages: 1876-1881

10.1377/hlthaff.2019.00243 | PMID 31682503 Get It

A primary care modification of family-based treatment for adolescent restrictive eating disorders
Lebow, Jocelyn , O’Brien, Janna R. Gewirtz , Mattke, Angela, Narr, Cassandra, Geske, Jennifer R. , Billings, Marcie, Clark, Matthew M. , Grange, Daniel Le , Sim, Leslie , Geske, Jennifer, Jacobson, Robert M. , Phelan, Sean, Le Grange, Daniel , Sim, Leslie A , Lebow, Jocelyn , Geske, Jennifer , Phelan, Sean M.

Mayo Clinic

Eating Disorders | November 1, 2019 | Volume: 29 | Issue: 4 | Pages: 376-389

10.1080/10640266.2019.1656468 | PMID 31675286 Get It

Clinical Predictors and Prognostic Impact of Recovery of Wall Motion Abnormalities in Takotsubo Syndrome: Results From the International Takotsubo Registry
Jurisic, Stjepan , Gili, Sebastiano , Cammann, Victoria L. , Kato, Ken , Szawan, Konrad A. , Bossone, Eduardo , Citro, Rodolfo , Sarcon, Annahita, Napp, L. Christian , Franke, Jennifer , Knorr, Maike, Heiner, Susanne, Burgdorf, Christof , Köenig, Wolfgang , Pott, Alexander , Kherad, Behrouz , Rajan, Lawrence, Michels, Guido, Pfister, Roman , Cuneo, Alessandro , Jacobshagen, Claudius, Karakas, Mahir , Meyer, Philippe , Arroja, José David , Banning, Adrian , Cuculi, Florim , Kobza, Richard , Fischer, Thomas, Vasankari, Tuija , Airaksinen, Juhani , Dworakowski, Rafał , Osswald, Stefan , Galiuto, Leonarda , Chan, Christina , Bridgman, Paul , Beug, Daniel , Kozel, Martin , Winchester, David E. , Gilyarova, Ekaterina, Gilyarov, Mikhail , El‐Battrawy, Ibrahim , Akın, İbrahim , Ukena, Christian , Poglajen, Gregor , Paolini, Carla , Bilato, Claudio , Carrilho‐Ferreira, Pedro , Pinto, Fausto J. , Opolski, Grzegorz , MacCarthy, Philip , Kobayashi, Yoshio , Prasad, Abhiram , Rihal, Charanjit S. , Widimský, Petr , Tschöpe, Carsten , Pieske, Burkert , Rottbauer, Wolfgang , Felix, Stephan B. , Borggrefe, Martin , Katus, Hugo A. , Münzel, Thomas , Böhm, Michael , Lüscher, Thomas F. , Ghadri, Jelena R. , Templin, Christian , Gilyarov, Mikhail , Bossone, Eduardo , Citro, Rodolfo , El-Battrawy, Ibrahim , Prasad, Abhiram , Tschöpe, Carsten , Koenig, Wolfgang , Meyer, Philippe , Banning, Adrian , Kobza, Richard , Gilyarov, Mikhail , Ukena, Christian , Bilato, Claudio , D’Ascenzo, Fabrizio , Jaguszewski, Miłosz , Noutsias, Michel , Kaiser, Christoph A. , Dichtl, Wolfgang , Delmas, Clément , Lairez, Olivier , Toušek, Petr , Shilova, Alexandra S. , Gałuszka, Jan , Rihal, Charanjit S. , Horowitz, John D. , Mario, Carlo Di , Crea, Filippo , Hasenfuß, Gerd , Braun-Dullaeus, Ruediger Christian , Thiele, Hölger , Bauersachs, Johann , Schunkert, Heribert , Bax, Jeroen J. , Ruschitzka, Frank T.

Mayo Clinic

Journal of the American Heart Association | November 1, 2019 | Volume: 8 | Issue: 21 | Pages: No page available

10.1161/jaha.118.011194 | PMID 31672100 Get It

Background Left ventricular ( LV ) recovery in takotsubo syndrome ( TTS ) occurs over a wide‐ranging interval, varying from hours to weeks. We sought to investigate the clinical predictors and prognostic impact of recovery time for TTS patients. Methods and Results TTS patients from the International Takotsubo Registry were included in this study. Cut‐off for early LV recovery was determined to be 10 days after the acute event. Multivariable logistic regression was used to assess factors associated with the absence of early recovery. In‐hospital outcomes and 1‐year mortality were compared for patients with versus without early recovery. We analyzed 406 patients with comprehensive and serial imaging data regarding time to recovery. Of these, 191 (47.0%) had early LV recovery and 215 (53.0%) demonstrated late LV improvement. Patients without early recovery were more often male (12.6% versus 5.2%; P =0.011) and presented more frequently with typical TTS (76.3% versus 67.0%, P =0.040). Cardiac and inflammatory markers were higher in patients without early recovery than in those with early recovery. Patients without early recovery showed unfavorable 1‐year outcome compared with patients with early recovery ( P =0.003). On multiple logistic regression, male sex, LV ejection fraction <45%, and acute neurologic disorders were associated with the absence of early recovery. Conclusions TTS patients without early LV recovery have different clinical characteristics and less favorable 1‐year outcome compared with patients with early recovery. The factors associated with the absence of early recovery included male sex, reduced LV ejection fraction, and acute neurologic events. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 01947621.